+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)


KOL Perspectives: Adaptive Trial Designs in IBD

  • ID: 4701806
  • Drug Pipelines
  • August 2018
  • Region: Global
  • 27 pages
  • GlobalData
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 4


  • AbbVie
  • Gilead
  • Janssen
  • MORE

This KOL Insight briefing focuses on KOLs views of Adaptive trial designs in IBD.

Questions topics -
  • Current challenges in IBD clinical trials
  • Adaptive Phase II/III trial designs
  • Guselkumab’s Phase II/III trial in Crohn’s disease
  • Novel clinical trials in IBD
Key Highlights
  • Most KOLs highlighted that recruitment is the greatest challenge in IBD clinical trials, both across Crohn’s disease & UC
  • Most KOLs flagged Phase II/III trials could accelerate development, but may limit ability to analyze data & adapt trial design
  • Most KOLs cited 8-12 weeks as being the minimum duration of a Phase II trial in IBD, with open-label extensions favored by all KOLs.
  • The insight briefing is based on Sociable Pharma’s analysis of primary research with our IBD key opinion leaders (KOLs).
In total, we conducted interviews with 10 KOLs -
  • 5 Europe-based & 5 N. America-based
  • Interviews performed during July 2018
KOL data is analyzed to produce -
  • Charts summarizing KOL opinions
  • Chart call-outs of key information & details
  • KOL quotes
  • Summary of KOL reporting trends
  • Insight from Sociable Pharma's analysts
Reasons to Buy
  • Combines Qualitative & semi-quantitative insight from key opinion leaders on Adaptive trial designs in IBD
  • Includes insight & recommendations from our disease-specific healthcare analysts
  • Utilizes independent expert viewpoints to validate the impact of new clinical data & emerging trends on management of IBD
  • Provides cost-effective support for your advisory boards, with topics acting as a catalyst for further expert discussion.
Note: Product cover images may vary from those shown
2 of 4


  • AbbVie
  • Gilead
  • Janssen
  • MORE
  • Executive Summary
  • Background
  • Research Panel Composition
  • Results & Implications
  • Appendix
Note: Product cover images may vary from those shown
3 of 4


4 of 4
  • Janssen
  • AbbVie
  • Gilead
Note: Product cover images may vary from those shown